C
Centessa Pharmaceuticals
Merger of ten pharmaceutical companies developing drugs for sleep-wake disorders, neurological conditions and cancer
At a glance
- Founded
- 2021
- Headquarters
- Boston, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
- BPBVF Partners
Cormorant Asset Management
General Atlantic- LCLogos Capital
- BCBoxer Capital
- SBSamsara BioCapital
T. Rowe Price
Franklin Templeton Investments- ECEcoR1 Capital
- LPLifeSci Venture Partners
Janus Henderson Investors
Wellington Management
Venrock- VVVida Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
43 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Centessa Pharmaceuticals was the backer or acquirer, 2021–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
10 deals across Centessa Pharmaceuticals's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Centessa Pharmaceuticals's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Centessa Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Centessa Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.